SARS-CoV-2 Infection: a Hurricane That Does Not Ignore Chronic Hepatitis

Overview

Journal Infection

Date 2022 Mar 22

PMID 35316530

Authors

Caterina Sagnelli

Margherita Macera

Clarissa Camaioni

Annabella Salvati

Nicola Coppola

Evangelista Sagnelli

Affiliations

Soon will be listed here.

Abstract

Background: The COVID-19 pandemic significantly compromised screening, laboratory controls, clinical surveillance and treatment of chronic hepatitis patients and worsened their outcome, as evidenced by its significant correlation with advanced cirrhosis, liver decompensation and mortality.

Results: This pandemic significantly impaired also the sector of liver transplantation, whose wards, operating rooms, outpatients' facilities, and healthcare personnel have been dedicated to patients with COVID-19. In addition, screening and treatment for HBV infection have been delayed or suspended in in most countries, with an increased risk of viral reactivation. Similar delay or suspension have also occurred for universal hepatitis B vaccination programs in many countries. Likewise, COVID-19 pandemic has made unreachable the goal of elimination of HCV infection as a worldwide public-health issue predicted for 2030 by the WHO.

Conclusion: This review article demonstrates how COVID-19 pandemic is causing serious damage to the sector of liver disease, which has quickly lost the beneficial effects of years of study, research, and clinical and technological application, as well as considerable financial investments.

Citing Articles

Effectiveness of test-and-treat model with direct-acting antiviral for hepatitis C virus infection in migrants: a prospective interventional study in Italy.

Coppola N, Alessio L, De Pascalis S, Macera M, Di Caprio G, Messina V Infect Dis Poverty. 2024; 13(1):39.

PMID: 38802954 PMC: 11131219. DOI: 10.1186/s40249-024-01200-9.

Changes in Spectrum of Respiratory Pathogen Infections and Disease Severity Among Children in Hohhot, China: Impact of COVID-19 Prevention Measures.

Gan Y, Yang P, Liu R, Wang Y, Hu Y, Yang Y Med Sci Monit. 2024; 30:e942845.

PMID: 38451880 PMC: 10929288. DOI: 10.12659/MSM.942845.

COVID-19, Possible Hepatic Pathways and Alcohol Abuse-What Do We Know up to 2023?.

Michalak A, Lach T, Szczygiel K, Cichoz-Lach H Int J Mol Sci. 2024; 25(4).

PMID: 38396888 PMC: 10888568. DOI: 10.3390/ijms25042212.

Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era.

Brzdek M, Zarebska-Michaluk D, Rzymski P, Lorenc B, Kazek A, Tudrujek-Zdunek M World J Gastroenterol. 2023; 29(13):2015-2033.

PMID: 37155527 PMC: 10122793. DOI: 10.3748/wjg.v29.i13.2015.

Outcomes of Thoracoscopic Lobectomy after Recent COVID-19 Infection.

Leonardi B, Sagnelli C, Natale G, Leone F, Noro A, Opromolla G Pathogens. 2023; 12(2).

PMID: 36839529 PMC: 9958887. DOI: 10.3390/pathogens12020257.

References

Wegermann K, Wilder J, Parish A, Niedzwiecki D, Gellad Z, Muir A . Racial and Socioeconomic Disparities in Utilization of Telehealth in Patients with Liver Disease During COVID-19. Dig Dis Sci. 2021; 67(1):93-99. PMC: 7842167. DOI: 10.1007/s10620-021-06842-5. View

Fix O, Hameed B, Fontana R, Kwok R, McGuire B, Mulligan D . Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement. Hepatology. 2020; 72(1):287-304. PMC: 7262242. DOI: 10.1002/hep.31281. View

Xu L, Ying S, Hu J, Wang Y, Yang M, Ge T . Pneumonia in patients with cirrhosis: risk factors associated with mortality and predictive value of prognostic models. Respir Res. 2018; 19(1):242. PMC: 6280505. DOI: 10.1186/s12931-018-0934-5. View

Aghemo A, Masarone M, Montagnese S, Petta S, Ponziani F, Russo F . Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the Liver. Dig Liver Dis. 2020; 52(9):937-941. PMC: 7351426. DOI: 10.1016/j.dld.2020.07.008. View

Qi X, Liu Y, Wang J, Fallowfield J, Wang J, Li X . Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study. Gut. 2020; 70(2):433-436. PMC: 7815629. DOI: 10.1136/gutjnl-2020-321666. View

Qi X, Liu C, Jiang Z, Gu Y, Zhang G, Shao C . Multicenter analysis of clinical characteristics and outcomes in patients with COVID-19 who develop liver injury. J Hepatol. 2020; 73(2):455-458. PMC: 7162763. DOI: 10.1016/j.jhep.2020.04.010. View

Buti M, Dominguez-Hernandez R, Casado M . Impact of the COVID-19 pandemic on HCV elimination in Spain. J Hepatol. 2020; 74(5):1246-1248. PMC: 7749992. DOI: 10.1016/j.jhep.2020.12.018. View

Strauss A, Boyarsky B, Garonzik-Wang J, Werbel W, Durand C, Avery R . Liver transplantation in the United States during the COVID-19 pandemic: National and center-level responses. Am J Transplant. 2020; 21(5):1838-1847. PMC: 9800484. DOI: 10.1111/ajt.16373. View

Docherty A, Harrison E, Green C, Hardwick H, Pius R, Norman L . Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020; 369:m1985. PMC: 7243036. DOI: 10.1136/bmj.m1985. View

10.

Blach S, Kondili L, Aghemo A, Cai Z, Dugan E, Estes C . Impact of COVID-19 on global HCV elimination efforts. J Hepatol. 2020; 74(1):31-36. PMC: 7411379. DOI: 10.1016/j.jhep.2020.07.042. View

11.

Balas E, Jaffrey F, Kuperman G, Boren S, Brown G, Pinciroli F . Electronic communication with patients. Evaluation of distance medicine technology. JAMA. 1997; 278(2):152-9. View

12.

Zhang C, Shi L, Wang F . Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020; 5(5):428-430. PMC: 7129165. DOI: 10.1016/S2468-1253(20)30057-1. View

13.

Wang Q, Davis P, Xu R . COVID-19 risk, disparities and outcomes in patients with chronic liver disease in the United States. EClinicalMedicine. 2021; 31:100688. PMC: 7834443. DOI: 10.1016/j.eclinm.2020.100688. View

14.

Ji D, Qin E, Xu J, Zhang D, Cheng G, Wang Y . Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. J Hepatol. 2020; 73(2):451-453. PMC: 7141624. DOI: 10.1016/j.jhep.2020.03.044. View

15.

Yip T, Wong V, Lui G, Chow V, Tse Y, Hui V . Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID-19. Hepatology. 2021; 74(4):1750-1765. PMC: 8239872. DOI: 10.1002/hep.31890. View

16.

Lee J . Effect of COVID-19 on liver transplantation in Korea. Transpl Infect Dis. 2020; 22(5):e13384. PMC: 7361242. DOI: 10.1111/tid.13384. View

17.

Marjot T, Moon A, Cook J, Abd-Elsalam S, Aloman C, Armstrong M . Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. J Hepatol. 2020; 74(3):567-577. PMC: 7536538. DOI: 10.1016/j.jhep.2020.09.024. View

18.

Lee T, Kaiser T, Alloway R, Woodle E, Edwards M, Shah S . Telemedicine Based Remote Home Monitoring After Liver Transplantation: Results of a Randomized Prospective Trial. Ann Surg. 2019; 270(3):564-572. DOI: 10.1097/SLA.0000000000003425. View

19.

Iavarone M, DAmbrosio R, Soria A, Triolo M, Pugliese N, Del Poggio P . High rates of 30-day mortality in patients with cirrhosis and COVID-19. J Hepatol. 2020; 73(5):1063-1071. PMC: 7280108. DOI: 10.1016/j.jhep.2020.06.001. View

20.

Turco C, Lim C, Soubrane O, Malaquin G, Kerbaul F, Bastien O . Impact of the first Covid-19 outbreak on liver transplantation activity in France: A snapshot. Clin Res Hepatol Gastroenterol. 2020; 45(4):101560. PMC: 7649029. DOI: 10.1016/j.clinre.2020.10.005. View